Simulations Plus (NASDAQ:SLP) Receives Outperform Rating from William Blair

Simulations Plus (NASDAQ:SLP)‘s stock had its “outperform” rating reissued by equities researchers at William Blair in a report released on Tuesday,RTT News reports.

SLP has been the subject of a number of other reports. Wall Street Zen upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a report on Monday, April 28th. KeyCorp boosted their price objective on shares of Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Simulations Plus has an average rating of “Moderate Buy” and an average target price of $50.00.

Simulations Plus Trading Up 3.8%

Shares of NASDAQ SLP traded up $1.00 during midday trading on Tuesday, reaching $27.37. 154,178 shares of the stock were exchanged, compared to its average volume of 221,648. The company has a market capitalization of $550.44 million, a P/E ratio of 68.43 and a beta of 1.10. Simulations Plus has a 52-week low of $23.01 and a 52-week high of $50.11. The stock has a 50 day moving average price of $30.42 and a 200-day moving average price of $30.41.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The firm had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. During the same period in the previous year, the firm earned $0.20 earnings per share. Simulations Plus’s revenue was up 22.5% compared to the same quarter last year. On average, analysts forecast that Simulations Plus will post 1.09 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the transaction, the director now directly owns 3,344,157 shares of the company’s stock, valued at approximately $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 19.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Fifth Third Bancorp lifted its position in shares of Simulations Plus by 33.8% during the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock worth $36,000 after purchasing an additional 375 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Simulations Plus by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company’s stock worth $254,000 after purchasing an additional 380 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock worth $34,000 after purchasing an additional 427 shares in the last quarter. Pitcairn Co. lifted its position in shares of Simulations Plus by 10.8% during the fourth quarter. Pitcairn Co. now owns 7,310 shares of the technology company’s stock worth $204,000 after purchasing an additional 711 shares in the last quarter. Finally, US Bancorp DE raised its holdings in Simulations Plus by 14.3% in the fourth quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock valued at $159,000 after acquiring an additional 713 shares in the last quarter. 78.08% of the stock is owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.